NanoPass Technologies has expanded its commercial presence in Mexico through a new distribution agreement for its MicronJet intradermal delivery platform. The expansion is part of the company’s broader global growth, which now includes Singapore, Colombia, and Australia, bringing NanoPass’s operations to over 30 countries.
Daniel Levitats, CEO, NanoPass Technologies, says that the expansion is a milestone in the company’s evolution. “Our goal is to make MicronJet the universal gold standard for intradermal delivery across aesthetics, vaccines, and advanced therapeutics by combining MEMS technology precision with unmatched patient comfort,” he says. Tal Shlezinger, Vice President of Sales and Marketing, NanoPass Technologies, adds that partners and clinicians worldwide are showing “tremendous momentum,” citing the platform’s proven results and patient-friendly design.
MicronJet replaces traditional stainless-steel needles with silicon-crystal pyramids less than 1mm long, allowing precise delivery into the dermis. The platform has been evaluated in more than 70 clinical studies and is approved in major markets, including the United States, the European Union, Canada, South Korea, Brazil, and China. NanoPass offers two models: MicronJet 600, used for skin rejuvenation, pigmentation, scar revision, hyperhidrosis, and local anesthesia, and the newly launched MicronJet 800, optimized for high-viscosity formulations and hair restoration.
The expansion into Mexico aligns with growing interest in regenerative and minimally invasive dermatology across Latin America. Recent industry discussions, such as Galderma’s GAIN Latam event in São Paulo, highlighted advances in injectable aesthetics and skin regeneration. The meeting brought together over 500 physicians from Brazil, Argentina, Colombia, Chile, and Mexico to discuss treatments like Sculptra, a collagen biostimulator, and Alastin, a skincare line designed to support skin renewal.
Experts at the event emphasized the role of collagen stimulation in maintaining skin structure and discussed how metabolic changes, including weight loss treatments, may affect skin appearance and patient expectations. Galderma also noted that in a global study of over 1,000 patients, 62% sought medical guidance for aesthetic procedures aimed at restoring natural skin appearance, with Sculptra being the most requested option among nearly half of respondents.
NanoPass’s entry into Mexico positions the MicronJet platform to support aesthetic and medical applications in the country, combining precision delivery with patient comfort. The company is also advancing clinical studies with pharmaceutical partners in vaccines, immunotherapy, local anesthesia, and ocular applications, demonstrating the platform’s versatility beyond aesthetics.
As the platform becomes available in Mexico, NanoPass expects the distribution agreement to strengthen access to intradermal delivery systems and support qualified health professionals in providing treatments based on scientific precision and clinical evidence.
Mexico is readily adopting minimally invasive surgical procedures. According to the Mexican Association of General Surgery, over 60% of elective surgeries in tertiary-level hospitals are performed using minimally invasive techniques, explains Victor Matos, Senior Commercial Director Johnson & Johnson, on MBN. “Medicine has undergone a radical transformation in recent years. The emergence of new technologies like AI, telemedicine, and advanced medical devices has changed the way we diagnose, treat, and monitor diseases. For doctors, this represents an opportunity to improve patient outcomes, offer evidence-based treatments, and utilize cutting-edge techniques that make surgeries less invasive, with more predictable results and faster recovery times,” he writes.